News & Updates

Upgrade Subscription

28 January 2025

Biopharmaceuticals Industry News Investments

Umoja Biopharma Raises $100 million in Series C Funding Round

Umoja Biopharma, a US biotech company focused on the development of immunotherapy treatments of cancerous cells, has raised $100 million in a Series C funding round, co-led by DCVC bio and Doiuble Point Ventures, with involvement from other new and existing life-science investors.

The funds will be used to enable Umoja to progress its in vivo CAR T cell therapy pipeline, namely its leading CD22 UB-VV400 program in many autoimmunology and oncology clinical studies.

Get started today.

PharmaChem Investor is your all-in-one solution for making strategic decisions, and driving innovation in the dynamic world of pharmaceuticals.

We notice you're using a small screen...

PharmaChem Investor is designed and optimised best for desktop devices and large screens, to make the most of all of the data available. We recommend accessing the site on a desktop device.

Logout